SCHEMBL7050882

SCHEMBL7050882

CC(C)(C)OC(=O)Nc1ccc(Oc2cncc(Cl)c2C=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.44
NAMPT P43490 1/20 0.42
MAPKAPK2 P49137 3/20 0.40
ATR Q13535 1/20 0.39
CCNC P24863 2/20 0.39
CDK8 P49336 2/20 0.39
ICAM1 P05362 1/20 0.39
SELE P16581 1/20 0.39
PSMB8 P28062 1/20 0.38
TGM2 P21980 2/20 0.37
F13A1 P00488 1/20 0.37
TGM1 P22735 1/20 0.37
ESRRA P11474 1/20 0.37
XIAP P98170 1/20 0.37
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873867 0.77 CYP17A1 (0.51) CYP17A1NAMPTPSMB8IDO1GAA
SCHEMBL13548240 0.77 CYP17A1 (0.51) CYP17A1NAMPTPSMB8IDO1GAA
SCHEMBL1122289 0.75 MAPKAPK2 (0.48) CYP17A1NAMPTMAPKAPK2ATRPSMB8
SCHEMBL29131710 0.75 HPGD (0.59) CYP17A1NAMPTPSMB8ALDH1A1GAA
SCHEMBL20131942 0.74 HPGD (0.49) CYP17A1NAMPTPSMB8ALDH1A1GAA
SCHEMBL30682542 0.74 HPGD (0.55) CYP17A1NAMPTPSMB8ESRRAXIAP
SCHEMBL2410967 0.73 CYP17A1 (0.45) CYP17A1NAMPTMAPKAPK2CDK8PSMB8
SCHEMBL23637726 0.73 CYP17A1 (0.63) CYP17A1NAMPTPSMB8SMN1; SMN2
SCHEMBL28880742 0.72 PNLIP (0.52) MAPKAPK2ESRRAXIAPGAAMEN1
SCHEMBL7058535 0.72 ICAM1 (0.76) CCNCCDK8ICAM1SELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 US disclosed
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
US-6232320-B1 THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES ABBOTT LABORATORIES 2001-05-15 US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM CYP17A1 1293/4885NAMPT 2975/4885MAPKAPK2 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.